What smart money is saying about Liquidia Corporation
2 funds in our archive have pitched Liquidia Corporation — most recently Arquitos Capital Management in December 2025.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Get an email when a fund writes about it
Position history
Between Q4 2025 and Q2 2026, 2 fund letters reported a position in Liquidia Corporation — 1 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 2 | 0 | 1 | 0 |
| Q4 2025 | 0 | 0 | 0 | 2 |
Fund activity · 2 positions · 1 move
- June 2026
“Liquidia Corp. (LQDA) – Liquidia makes YUTREPIA, a drug that launched one year ago to treat Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Interstitial Lung Diseases (PH- ILD).”
Liquidia Corporation - TrimmedGreenhaven Road Capital FundJune 2026
“Liquidia (LQDA) — This is another special situation. The company has launched a successful drug but remains in a patent dispute that will determine how large their market can be. We purchased shares below where I believed they would settle even after an adverse trial outcome. The shares appreciated more than 30% before a verdict, so we realized a short-term gain and will revisit the investment after the decision.”
Liquidia Corporation
Fund coverage · 2 theses
- Arquitos Capital ManagementDecember 2025
Liquidia is a pulmonary hypertension drug company with a superior PRINT-based inhaled treprostinil launch, rapid market share gains, strong early cash flow, large pipeline opportunities, and potential upside from legal resolution and M&A.
Read the full thesis - Laughing Water CapitalDecember 2025
Liquidia Corporation has an approved, better-tolerated PAH/PH-ILD therapy gaining share with patent outcomes skewed favorably, creating substantial upside with manageable downside.
Read the full thesis
Read every full thesis on Liquidia Corporation
Unlock all 2 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→